Last updated on November 2016

Clinical Protocol MB102230

Brief description of study

Clinical Protocol MB102230

Detailed Study Description

A Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects with Type 1 Diabetes Mellitus.

Clinical Study Identifier: TX145993

Find a site near you

Start Over

Diabetes Associates Medical Group / Clinical Research

1234 W. Chapman Ave., Suite 106 Orange, CA USA
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.